BMO Hosts Second Annual Obesity Summit on the Future of the GLP-1+ Market
BMO is set to host its second annual Obesity Summit on March 25, 2025, in New York, focusing on the expanding $150 billion obesity therapies market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BMO is set to host its second annual Obesity Summit on March 25, 2025, in New York, focusing on the expanding $150 billion obesity therapies market. The summit will bring together healthcare industry experts and leaders to examine trends in metabolic disease and drug therapies.
The event features prominent companies including Altimmune, Amgen, Corbus Pharmaceuticals, Eli Lilly, FlyteHealth, Novo Nordisk, Roman Health, Scholar Rock, and Structure Therapeutics. Participants will explore advances in GLP-1 drug therapies with insights from pharmacy benefit managers, patients, and providers.
The summit's agenda includes fireside chats, expert panels, and presentations featuring BMO Sr. Biotechnology & Pharmaceuticals Analyst Evan Seigerman, FlyteHealth Co-Founder Dr. Katherine Saunders, and Dr. Louis J. Aronne, Sanford I. Weill Professor of Metabolic Research. Key topics include care delivery, emerging technologies, coverage and access, and patient insights on GLP-1+ therapy.
Positive
- BMO positioning itself as a thought leader in the rapidly growing $150 billion obesity therapies market
- High-profile participation from major pharmaceutical companies indicates strong industry engagement
Negative
- None.
Details
News Market Reaction – BMO
The recorded move for BMO in the trading session of this news was -0.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Healthcare industry experts and leaders to convene March 25 at the 2025 BMO Obesity Summit to examine outlook and trends in metabolic disease and drug therapies
What: | 2025 BMO Obesity Summit |
When: | Tuesday, March 25, 2025 |
Where: | Convene, 360 Madison Ave, |
Media: | Register here |
The BMO Obesity Summit will deliver thought leadership and corporate management perspectives in a variety of formats such as fireside chats, expert panels and presentations, including:
- Discussions with leading life sciences companies hosted by BMO analysts, including Sr. Biotechnology & Pharmaceuticals Analyst, Evan Seigerman
- Obesity 102 with Katherine Saunders, MD, Obesity Physician & Co-Founder, FlyteHealth
- A discussion with Dr. Louis J. Aronne, M.D., Sanford I. Weill Professor of Metabolic Research
- Panels on care delivery, emerging technologies, coverage and access
- Insights from patients on GLP-1+ therapy
For more information or to request an interview with one of BMO's equity research analysts, please contact BMO Media Relations using the contact details below. Note: There may be restrictions for media on access to some presentations.
About BMO Financial Group
BMO Financial Group is the eighth largest bank in North America by assets, with total assets of
SOURCE BMO Financial Group
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.